GlassScriptPhysician profile
Nicole Kuhar
NPI 1235636788
$3,514.97
in general payments reported to CMS, 2019-2025
31 companies · $896 in 2025
The $896 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.49 · 2021: $165 · 2022: $536 · 2023: $985 · 2024: $921 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,802.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $884.81 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $514.70 | 2021-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $470.16 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.54 | 2021-2024 | Jardiance, Tradjenta |
| Lilly USA, LLC | $181.97 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $174.92 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $144.27 | 2022-2024 | |
| Glaxosmithkline, LLC. | $131.19 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $121.19 | 2023-2025 | |
| Exact Sciences Corporation | $115.17 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $72.81 | 2022-2023 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $41.18 | 2021-2025 | Zoryve |
| Hologic Sales and Service, LLC | $40.28 | 2023-2025 | Aptima |
| Janssen Pharmaceuticals, INC | $40.20 | 2021-2023 | Xarelto |
| Almatica Pharma LLC | $33.88 | 2024 | Teriparatide, Loreev Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $24.72 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $24.63 | 2021-2022 | |
| Radius Health, INC. | $22.14 | 2024 | |
| Inspire Medical Systems, INC. | $19.84 | 2025 | Inspire |
| Astellas Pharma US INC | $19.75 | 2024 | Veozah |
| Harmony Biosciences LLC | $18.65 | 2025 | |
| Lundbeck LLC | $18.39 | 2024 | Rexulti |
| Verona Pharma, INC. | $18.16 | 2025 | Ohtuvayre |
| Azurity Pharmaceuticals, INC. | $17.96 | 2025 | Horizant |
| Jazz Pharmaceuticals INC. | $14.94 | 2022 | |
| Alkermes, INC. | $14.42 | 2021 | |
| Esperion Therapeutics, INC. | $14.39 | 2024 | Nexletol |
| Shield Therapeutics INC | $13.57 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.52 | 2023 | |
| Genentech USA, INC. | $11.49 | 2019 | |
| Phathom Pharmaceuticals, INC. | $10.13 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Kuhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.